全文获取类型
收费全文 | 39554篇 |
免费 | 3218篇 |
国内免费 | 1893篇 |
专业分类
耳鼻咽喉 | 214篇 |
儿科学 | 557篇 |
妇产科学 | 641篇 |
基础医学 | 7968篇 |
口腔科学 | 978篇 |
临床医学 | 2938篇 |
内科学 | 6799篇 |
皮肤病学 | 704篇 |
神经病学 | 3563篇 |
特种医学 | 669篇 |
外国民族医学 | 15篇 |
外科学 | 2807篇 |
综合类 | 4814篇 |
现状与发展 | 8篇 |
预防医学 | 1543篇 |
眼科学 | 587篇 |
药学 | 5824篇 |
2篇 | |
中国医学 | 472篇 |
肿瘤学 | 3562篇 |
出版年
2024年 | 73篇 |
2023年 | 506篇 |
2022年 | 1037篇 |
2021年 | 1648篇 |
2020年 | 1136篇 |
2019年 | 1100篇 |
2018年 | 1007篇 |
2017年 | 973篇 |
2016年 | 1200篇 |
2015年 | 1406篇 |
2014年 | 1999篇 |
2013年 | 2428篇 |
2012年 | 2248篇 |
2011年 | 2543篇 |
2010年 | 2142篇 |
2009年 | 2269篇 |
2008年 | 2217篇 |
2007年 | 2114篇 |
2006年 | 1857篇 |
2005年 | 1639篇 |
2004年 | 1324篇 |
2003年 | 1160篇 |
2002年 | 853篇 |
2001年 | 847篇 |
2000年 | 701篇 |
1999年 | 638篇 |
1998年 | 615篇 |
1997年 | 628篇 |
1996年 | 522篇 |
1995年 | 502篇 |
1994年 | 464篇 |
1993年 | 395篇 |
1992年 | 393篇 |
1991年 | 358篇 |
1990年 | 340篇 |
1989年 | 317篇 |
1988年 | 281篇 |
1987年 | 268篇 |
1986年 | 259篇 |
1985年 | 375篇 |
1984年 | 335篇 |
1983年 | 227篇 |
1982年 | 284篇 |
1981年 | 236篇 |
1980年 | 191篇 |
1979年 | 138篇 |
1978年 | 119篇 |
1977年 | 101篇 |
1976年 | 79篇 |
1975年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
以钒基核苷酸复合物为核酸酶抑制剂,从人胚组织中制备总RNA,所得产品几乎不含DNA和蛋白质,经过分离Poly(A)~ mRNA,证明制品有合成cDNA的完整功能,方法比较简捷,适于大量制备以满足分离mRNA 之需,并讨论了此法的优缺点。 相似文献
52.
ALVARO MARTÍNEZ DEL POZO MARIA GASSET MERCEDES O
ADERRA JOS G. GAVILANES 《Chemical biology & drug design》1989,34(5):416-422
α-Sarcin binds one Zn(II) cation per protein molecule, with a Kd value of 0.9 mM, determined by equilibrium dialysis experiments. Ca(II), Mg(II), and Mn(II) do not bind to α-sarcin. Cd(II) and Co(II) also behave as Zn(II). The binding produces local modifications on the protein conformation affecting the microenvironment of tryptophan residues. The three cations modify the fluorescence emission of the protein. The near-u. v. circular dichroism spectrum of the protein is also altered. The binding of Zn(II) and related cations does not modify the secondary structure of the protein. The ribonucleolytic activity of a-sarcin is inhibited upon Zn(II) binding, but no alteration of the ability of the protein to aggregate phospholipid vesicles has been observed. 相似文献
53.
54.
目的运用siRNA技术在肝癌细胞株中建立稳定低表达人胰岛素样生长因子1类受体(IGF1R)基因的细胞株。方法构建包含封闭IGF1R基因的真核表达载体pSUPER-IGF1R-siRNA,转染SMMC7721和Hep3B细胞,G418筛选表达稳定的细胞株。通过RT-PCR、Western-blot分析与鉴定IGF1R mRNA和蛋白及cyclin D1、cyclinB1蛋白的表达,并绘制细胞生长曲线。结果在SMMC7721和Hep3B细胞中成功建立低表达IGF1R基因的细胞株,其生长明显减慢(P<0.05),且其cyclinD1表达亦明显下降(P<0.05)。结论pSUPER-IGF1R-siRNA能抑制SMMC7721和Hep3B细胞的生长。 相似文献
55.
目的:探讨胰岛素样生长因子 I(IGF-Ⅰ)和胰岛素样生长因子结合蛋白 1(IGFBP—1)与妊高征(PIH)的关系。方法:采用免疫放射法测定50例妊高征孕妇(PIH组)和108例正常孕妇(对照组)的血清 IGF-Ⅰ、IGFBP-1水平,并对其结果进行相关性分析。结果:①妊高征孕妇血清 IGF-Ⅰ水平低于正常孕妇(P<0.05),且重度妊高征孕妇血清 IGF-Ⅰ水平低于中度和轻度孕妇(P<0.05,P<0.01)。②妊高征孕妇血清 IGFBP-1水平高于正常孕妇(P<0.05),且重度妊高征孕妇血清 IGFBP-1水平高于中度和轻度孕妇(P<0.05,P<0.01)。③两组孕妇血清 IGF-Ⅰ水平与血清 IGFBP-1水平呈负相关(r=-0.386,P<0.05)。④妊高征孕妇血清 IGF-Ⅰ水平与舒张压呈负相关(r=-0.386,P<0.05),血清 IGFBP-1水平与舒张压呈正相关(r=0.632,P<0.01)。结论:妊高征孕妇血清 IGF-Ⅰ、IGFBP-1水平的高低可反映妊高征的严重程度。 相似文献
56.
目的:观察核心结合因子a1(Cbfa1)对兔骨髓间充质干细胞(MSCs)向成骨细胞分化的诱导作用。方法:体外分离培养兔骨髓MSCs,用AdEasy1/Cbfa1。转染MSCs,在转染后3d,1、2、3和4周时,组织化学和免疫组化等方法检测成骨标志碱性磷酸酶和骨钙素的表达。结果:AdEasy1/Cbfa1转染后的兔骨髓MSCs表现出与成骨细胞相似的形态,并且表达碱性磷酸酶和骨钙素。结论:Cbfa1可诱导兔骨髓MSCs向成骨细胞分化。 相似文献
57.
The pathogenesis of heart hypertrophy and failure have been the focus of intense clinical and basic science investigation,
yet the signal transduction pathways and molecular process that underlie the compensatory growth process that ultimately leads
to heart failure remain enigmatic. Since ventricular myocytes have exited the cell cycle, growth of the myocardium in response
to hemodynamic load occurs by cellular hypertrophy and not by hyperplasia. In this article, we document the potential involvement
of tumor suppressor pocket proteins and cell cycle regulators that may impinge on the growth, differentiation, and apoptosis
of cardiac muscle.
This revised version was published online in August 2006 with corrections to the Cover Date. 相似文献
58.
59.
K. R. Afugupalli S. Kalfas S. Edwardsson A. S. Naidu 《Oral microbiology and immunology》1995,10(1):35-41
The interaction of lactoferrin with Actinobacillus actinomycetemcomitans was examined in a 125 I-labeled protein binding assay. The binding of human and bovine lactoferrins reached maximum within 1 h. Lactoferrin binding to the bacterium was pH-dependent and reversible. Scatchard analysis indicated the existence of two different types of binding sites on the bacterium, one with a high affinity constant kα =8.8×10−7 M) and the other with a low one (kα =1.8×10−6 M). Bacteria in the exponential phase of growth showed higher binding than cells in the stationary phase. Bacteria grown in medium containing serum and/or lysed erythrocytes bound lactoferrin to a lesser extent. Heat-inactivated serum, lysed erythrocytes and other proteins such as mucin and laminin inhibited lactoferrin binding to A. actinomycetemcomitans in a competitive binding assay. Sodium dodecyl sulfate polyacrylamidegel electrophoresis and Western blot analysis of the cell envelope as well as the outer membrane of A. actinomycetemcomitans revealed lactoferrin-reactive protein bands at 29 kDa and 16.5 kDa. The 29-kDa band displayed a heat-modifiable lactoferrin-reactive form with a molecular weight of 34 kDa. Neither proteinase K-treated cell envelope nor lipopolysaccharide of this bacterium showed reactivity with lactoferrin. These data suggests a specific interaction of lactoferrin with outer membrane proteins of A. actinomycetemcomitans . 相似文献
60.
Purification of antigenically intact Ro ribonucleoproteins; biochemical and immunological evidence that the 52-kD protein is not a Ro protein. 总被引:3,自引:0,他引:3
下载免费PDF全文
![点击此处可从《Clinical and experimental immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
G Boire M Gendron N Monast B Bastin H A Mnard 《Clinical and experimental immunology》1995,100(3):489-498
Anti-Ro sera immunoprecipitate Ro ribonucleoproteins (RNPs) from human cell extracts. Ro RNPs are biochemically heterogeneous particles whose functions are unknown and whose exact composition remains controversial. In addition to 60-kD Ro and to La proteins, a 52-kD polypeptide (p52) has been proposed to be a stable component of the Ro RNPs. To confirm the immunological studies supporting this hypothesis, we have biochemically purified Ro RNPs from HeLa cells using non-denaturing conditions. Ro RNPs segregated into three distinct populations, one of which only contained hY5 RNA (RohY5 RNPs). No p52 co-purified with Ro RNPs. Despite the absence of p52, purified Ro RNPs had biochemical and immunological properties identical to those of unfractionated Ro RNPs. Many anti-Ro sera only recognize p52 in immunoblots, and are said to be monospecific anti-p52. Preincubation with purified RohY5 RNPs (free of p52) of all human anti-Ro (including so-called monospecific anti-p52) sera abolished their capacity to immunoprecipitate Ro RNPs from unfractionated HeLa cell extracts. Conversely, preincubation of anti-Ro sera with purified p52 protein specifically inhibited recognition of p52 in immunoblots, but did not interfere with immunoprecipitation of Ro RNPs. Our data demonstrate that anti-p52 antibodies do not target intact Ro RNPs, nor do they target the native 60-kD Ro protein. Contrary to previous reports, p52 protein is not a stable component of antigenically intact Ro RNPs. 相似文献